The 1.6.1 monoclonal antibody specifically binds to the human Thrombopoietin Receptor (TPO-R) that is also known as the Myeloproliferative leukemia protein (c-Mpl) or CD110. CD110 is a type I transmembrane glycoprotein and a member of the hematopoietin receptor family. It is expressed on hematopoietic stem cells, a subfraction of hematopoietic precursor cells, cells of the megakaryocytic lineage and platelets. CD110 serves as a receptor for thrombopoietin. Upon binding of thrombopoietin to CD110, megakaryocyte proliferation and differentiation is induced, platelets are produced and stem cells are protected from apoptosis.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.
NOTE: The BD Rhapsody Single-Cell Analysis System must be used with the BD Rhapsody Express Instrument.